BACKGROUND: Whole-body magnetic resonance imaging (wbMRI) allows general assessment of systemic cancers including lymphomas without radiation burden. AIM: To evaluate the diagnostic performance of wbMRI in the staging of diffuse large B-cell lymphoma (DLBCL), determine the value of individual MRI sequences, and assess patients' concerns with wbMRI. METHODS: In this single-center prospective study, adult patients newly diagnosed with systemic DLBCL underwent wbMRI on a 3T scanner [diffusion weighted images with background suppression (DWIBS), T2, short tau inversion recovery (STIR), contrast-enhanced T1] and fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) (reference standard). The involvement of 12 nodal regions and extranodal sites was evaluated on wbMRI and PET/CT. The utility of wbMRI sequences was rated on a five-point scale (0 = not useful, 4 = very useful). Patients received a questionnaire regarding wbMRI. RESULTS: Of 60 eligible patients, 14 (23%) were enrolled and completed the study. The sensitivity of wbMRI in the nodal involvement (182 nodal sites) was 0.84, with 0.99 specificity, positive predictive value of 0.96, negative predictive value of 0.97, and 0.97 accuracy. PET/CT and wbMRI were concordant both in extranodal involvement (13 instances) and staging (κ = 1.0). The mean scores of the utility of MRI sequences were 3.71 ± 0.73 for DWIBS, 2.64 ± 0.84 for T1, 2.14 ± 0.77 for STIR, and 1.29 ± 0.73 for T2 (P < 0.0001). Patients were mostly concerned about the enclosed environment and duration of the MRI examination (27% of patients). CONCLUSION: The wbMRI exhibited excellent sensitivity and specificity in staging DLBCL. DWIBS and contrast-enhanced T1 were rated as the most useful sequences. Patients were less willing to undergo wbMRI as a second examination parallel to PET/CT, especially owing to the long duration and the enclosed environment.

1st Department of Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague Prague 12808 Czech Republic

Department of Imaging Methods Motol University Hospital and 2nd Faculty of Medicine Charles University Prague 15006 Czech Republic

Department of Radiology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague 12808 Czech Republic

Institute of Nuclear Medicine 1st Faculty of Medicine Charles University and General University Hospital Prague Prague 12808 Czech Republic

Zobrazit více v PubMed

Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español de Médula Ósea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–3068. PubMed PMC

Lambert L, Burgetova A, Trneny M, Bircakova B, Molinsky J, Benesova K, Zogala D, Michalek P. The diagnostic performance of whole-body MRI in the staging of lymphomas in adult patients compared to PET/CT and enhanced reference standard-systematic review and meta-analysis. Quant Imaging Med Surg. 2022;12:1558–1570. PubMed PMC

Yoo KH. Staging and response assessment of lymphoma: a brief review of the Lugano classification and the role of FDG-PET/CT. Blood Res. 2022;57:75–78. PubMed PMC

Barrington SF, Mikhaeel NG. PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas. Curr Hematol Malig Rep. 2016;11:185–195. PubMed PMC

Kostakoglu L, Martelli M, Sehn LH, Belada D, Carella AM, Chua N, Gonzalez-Barca E, Hong X, Pinto A, Shi Y, Tatsumi Y, Knapp A, Mattiello F, Nielsen T, Sahin D, Sellam G, Oestergaard MZ, Vitolo U, Trněný M. End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. Blood Adv. 2021;5:1283–1290. PubMed PMC

Hagtvedt T, Seierstad T, Lund KV, Løndalen AM, Bogsrud TV, Smith HJ, Geier OM, Holte H, Aaløkken TM. Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma. Acta Radiol. 2015;56:152–158. PubMed

Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgués JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. N Engl J Med. 2022;386:351–363. PubMed PMC

Vitolo U, Trněný M, Belada D, Burke JM, Carella AM, Chua N, Abrisqueta P, Demeter J, Flinn I, Hong X, Kim WS, Pinto A, Shi YK, Tatsumi Y, Oestergaard MZ, Wenger M, Fingerle-Rowson G, Catalani O, Nielsen T, Martelli M, Sehn LH. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017;35:3529–3537. PubMed

Davies AJ, Barrans S, Stanton L, Caddy J, Wilding S, Saunders G, Mamot C, Novak U, McMillan A, Fields P, Collins GP, Stephens R, Cucco F, Sha C, van Hoppe M, Tooze R, Davies JR, Griffiths G, Schuh A, Burton C, Westhead DR, Du MQ, Johnson PWM. Differential Efficacy From the Addition of Bortezomib to R-CHOP in Diffuse Large B-Cell Lymphoma According to the Molecular Subgroup in the REMoDL-B Study With a 5-Year Follow-Up. J Clin Oncol. 2023;41:2718–2723. PubMed PMC

Abdulqadhr G, Molin D, Aström G, Suurküla M, Johansson L, Hagberg H, Ahlström H. Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients. Acta Radiol. 2011;52:173–180. PubMed

Fischerova D, Pinto P, Burgetova A, Masek M, Slama J, Kocian R, Frühauf F, Zikan M, Dusek L, Dundr P, Cibula D. Preoperative staging of ovarian cancer: comparison between ultrasound, CT and whole-body diffusion-weighted MRI (ISAAC study) Ultrasound Obstet Gynecol. 2022;59:248–262. PubMed

Kaalep A, Sera T, Oyen W, Krause BJ, Chiti A, Liu Y, Boellaard R. EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems. Eur J Nucl Med Mol Imaging. 2018;45:412–422. PubMed PMC

Hofman MS, Smeeton NC, Rankin SC, Nunan T, O'Doherty MJ. Observer variation in interpreting 18F-FDG PET/CT findings for lymphoma staging. J Nucl Med. 2009;50:1594–1597. PubMed

El-Galaly TC, Gormsen LC, Hutchings M. PET/CT for Staging; Past, Present, and Future. Semin Nucl Med. 2018;48:4–16. PubMed

Littooij AS, Kwee TC, de Keizer B, Bruin MC, Coma A, Beek FJ, Fijnheer R, Nievelstein RA. Whole-body MRI-DWI for assessment of residual disease after completion of therapy in lymphoma: A prospective multicenter study. J Magn Reson Imaging. 2015;42:1646–1655. PubMed

Wang D, Huo Y, Chen S, Wang H, Ding Y, Zhu X, Ma C. Whole-body MRI versus (18)F-FDG PET/CT for pretherapeutic assessment and staging of lymphoma: a meta-analysis. Onco Targets Ther. 2018;11:3597–3608. PubMed PMC

Abdel-aziz SMA, Badrelden SKM, Salama AMM. Utility of PET/CT for therapy response assessment in non-Hodgkin's lymphoma. QJM. 2021;114

Aamir F, Aslam I, Arshad M, Omer H. Accelerated Diffusion-Weighted MR Image Reconstruction Using Deep Neural Networks. J Digit Imaging. 2023;36:276–288. PubMed PMC

Jurka M, Macova I, Wagnerova M, Capoun O, Jakubicek R, Ourednicek P, Lambert L, Burgetova A. Deep-learning-based reconstruction of T2-weighted magnetic resonance imaging of the prostate accelerated by compressed sensing provides improved image quality at half the acquisition time. Quant Imaging Med Surg. 2024;14:3534–3543. PubMed PMC

Madl JEM, Nieto Alvarez I, Amft O, Rohleder N, Becker L. The Psychological, Physiological, and Behavioral Responses of Patients to Magnetic Resonance Imaging (MRI): A Systematic Review and Meta-Analysis. J Magn Reson Imaging. 2024;59:675–687. PubMed

Madl J, Janka R, Bay S, Rohleder N. MRI as a Stressor: The Psychological and Physiological Response of Patients to MRI, Influencing Factors, and Consequences. J Am Coll Radiol. 2022;19:423–432. PubMed

Taylor SA, Mallett S, Beare S, Bhatnagar G, Blunt D, Boavida P, Bridgewater J, Clarke CS, Duggan M, Ellis S, Glynne-Jones R, Goh V, Groves AM, Hameeduddin A, Janes SM, Johnston EW, Koh DM, Miles A, Morris S, Morton A, Navani N, O'Donohue J, Oliver A, Padhani AR, Pardoe H, Patel U, Punwani S, Quinn L, Rafiee H, Reczko K, Rockall AG, Shahabuddin K, Sidhu HS, Teague J, Thaha MA, Train M, van Ree K, Wijeyekoon S, Halligan S Streamline investigators. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectal cancer: the prospective Streamline C trial. Lancet Gastroenterol Hepatol. 2019;4:529–537. PubMed PMC

Manuweera T, Karunakaran K, Baechler C, Rosales J, Kleckner AS, Rosenblatt P, Ciner A, Kleckner IR. Barriers and Facilitators for Participation in Brain Magnetic Resonance Imaging (MRI) Scans in Cancer Research: A Feasibility and Acceptability Analysis. Res Sq. 2024.

Norbash A, Yucel K, Yuh W, Doros G, Ajam A, Lang E, Pauker S, Mayr N. Effect of team training on improving MRI study completion rates and no-show rates. J Magn Reson Imaging. 2016;44:1040–1047. PubMed PMC

Madl J, Janka R, Bay S, Sturmbauer SC, Rohleder N. Effects of video-based patient preparation for MRI on clinical processes and patient experience. Eur J Radiol. 2023;158:110621. PubMed

Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M, Sebban C, Belhadj K, Bordessoule D, Fermé C, Tilly H. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040–2045. PubMed PMC

Hong GS, Chae EJ, Ryu JS, Chae SY, Lee HS, Yoon DH, Suh C. Assessment of naive indolent lymphoma using whole-body diffusion-weighted imaging and T2-weighted MRI: results of a prospective study in 30 patients. Cancer Imaging. 2021;21:5. PubMed PMC

Kurch L, Kluge R, Sabri O, Fischer L, Wendt S, Graf Einsiedel H, Starke S, Kühl JS, Christiansen H, Hirsch FW, Sorge I, Roth C. Whole-body [(18)F]-FDG-PET/MRI for staging of pediatric non-Hodgkin lymphoma: first results from a single-center evaluation. EJNMMI Res. 2021;11:62. PubMed PMC

Husby T, Johansen H, Bogsrud T, Hustad KV, Evensen BV, Boellard R, Giskeødegård GF, Fagerli UM, Eikenes L. A comparison of FDG PET/MR and PET/CT for staging, response assessment, and prognostic imaging biomarkers in lymphoma. Ann Hematol. 2022;101:1077–1088. PubMed PMC

Picardi M, Cavaliere C, Della Pepa R, Nicolai E, Soricelli A, Giordano C, Pugliese N, Rascato MG, Cappuccio I, Campagna G, Cerchione C, Vigliar E, Troncone G, Mascolo M, Franzese M, Castaldo R, Salvatore M, Pane F. PET/MRI for staging patients with Hodgkin lymphoma: equivalent results with PET/CT in a prospective trial. Ann Hematol. 2021;100:1525–1535. PubMed PMC

Mistry V, Scott JR, Wang TY, Mollee P, Miles KA, Law WP, Hapgood G. Diagnostic performance of prospective same-day 18F-FDG PET/MRI and 18F-FDG PET/CT in the staging and response assessment of lymphoma. Cancer Imaging. 2023;23:11. PubMed PMC